SDS-PAGE纤维蛋白自显影法检测不同分子量的纤溶酶原激活剂

体内存在两种纤溶酶原激活剂(plasminogen activator, PA):血液中生理性的组织型纤溶酶原激活剂(t PA)及尿中的尿激酶型纤溶酶原激活剂(u PA)。它们通过将纤溶酶原转变成有活性的纤溶酶而启动纤溶过程使血栓溶解。目前模拟体内纤溶过程以纤维蛋白为底物的PA物质活性测定方法有纤维蛋白溶圈法和发光分析法,但这两种方法不能     

重组人糖基化尿型纤溶酶原激活剂中试产品抗原特异性的分析

尿型纤溶酶原激活剂（ｕ－ＰＡ）是新一代的基因工程溶栓药物。建立了重组人糖基化尿型纤溶酶原激活剂的中试生产工艺。中试产品的结构正确性和一致性分析是证明产品质量的重要依据,所以,对三批产品进行了抗原特异性分析。结果,ｕ－ＰＡ三批中试产品ＳＤＳ－ＰＡＧＥ显示的蛋白区带与免疫印迹显示的免疫活性区带没有批次判别说明ｕ－ＰＡ三批中试产品表现了一致的ｕ－ＰＡ的免疫原性。     

尿激酶型纤溶酶原激活剂的研究

尿激酶型纤溶酶原激活剂u-PA(urokinase-type plasminogen activator)属于丝氨酸蛋白酶类,能激活细胞外基质中丰富的纤溶酶原生成纤溶酶,从而催化细胞外基质降解,对纤溶和癌细胞侵染及扩散等一系列生理和病理过程中发生的胞外蛋白水解起重要调节作用。 人u-PA基因位于第10号染色体之上,表达产生一个约54kD的单链糖基化多肽——尿激酶原。尿激酶原经纤溶酶在其158位赖氨酸     

溶栓剂研究的新进展

近年来对溶栓剂在研究取得了很好的成果,主要集中在单链酶型纤溶酶原激活剂（scu-PA),组织型纤溶酶原激活剂（t-PA),葡萄球菌激酶（SAK）等,对分子进行设计改造,保留它们高效的溶栓功能同时赋予新的功能,在对分子空间结构域和活性功能区分析的基础上,研制出更有效的,更安全的溶栓制剂具有广阔的发展前景。     

溶栓剂研究的新进展

近年来对溶栓剂的研究取得了很好的成果 ,主要集中在单链尿激酶型纤溶酶原激活剂 (scu PA) ,组织型纤溶酶原激活剂 (t PA) ,葡萄球菌激酶 (SAK)等 ,对分子进行设计改造 ,保留它们高效的溶栓功能同时赋予新的功能。在对分子空间结构域和活性功能区分析的基础上 ,研制出更有效的、更安全的溶栓制剂具有广阔的发展前景。     

纤溶酶原在金黄色葡萄球菌感染中的作用

金黄色葡萄球菌菌体表面有多种纤溶酶原受体,包括次黄嘌呤单核苷酸脱氢酶、核糖核苷酸还原酶、α-烯醇化酶和3-磷酸甘油醛脱氢酶等,它们均可以与纤溶酶原结合。与细菌结合的纤溶酶原可被宿主的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)或葡萄菌属的纤溶酶原激活剂(葡激酶)激活为纤溶酶。细菌表面的纤溶酶有利于其降解宿主胞外基质,穿越组织屏障,因此哺乳动物的纤溶酶原可能在金黄色葡萄球菌感染宿主过程中起重要作用。     

具有纤溶活性作用的海洋真菌代谢产物的分离与菌株鉴定

本文旨在分离具有纤溶活性作用的化合物和鉴定产生纤溶活性化合物的菌株FG216的种属分类。以马铃薯蔗糖培养基为种子培养基,改良查氏培养基为发酵培养基对菌株进行发酵培养,用甲醇作为提取溶剂,通过半制备型高效液相色谱从真菌FG216的1 L发酵液中分离和精制了12 mg纤溶活性化合物,该纤溶活性化合物在纤溶酶原和单链尿激酶性纤溶酶原激活剂相互活化反应体系中添加10μg/mL活性最高。对FG216菌株rDNA的ITS基因(ITS-5.8 S rDNA)进行PCR扩增、测序,从GenBank获取相似序列,通过序列比对分析和系统发育分析表明菌株FG216与Stachybotrys longispora同源性最高。从分离的海洋微生物葡萄穗霉属菌株FG216分离得到的纤溶活性化合物具体促进纤溶酶原和单链尿激酶性纤溶酶原激活剂相互活化的作用。     

重组纤溶酶原激活剂抑制剂－2基因在HT1080亚克隆中的表达

重组纤溶酶原激活剂抑制剂－２基因在ＨＴ１０８０亚克隆中的表达曹祥荣（南京师范大学生物学系,２１００２４）关键词纤溶酶原激活剂,基因重组,纤溶酶原激活剂抑制剂活性表达目前认为纤溶酶系统是肿瘤细胞浸润和转移蛋白水解过程中重要的酶,纤溶酶能直接水解细胞外间...     

葡萄球菌激酶作为新型溶栓剂的研究进展

近年来对溶栓剂的研究取得了很好的成果,主要集中在单链尿激酶型纤溶酶原激活剂(scuPA),组织型纤溶酶原激活剂(tPA),葡萄球菌激酶(SaK)等。葡萄球菌激酶(SaK)是一种激活溶纤维蛋白的制剂,它与纤溶酶原(Plg)形成1∶1的复合体,使后者转变为纤溶酶(Pli)后激活其他分子变为Pli。从葡激酶的溶栓作用机制,包括与纤溶酶(原)等因子的结合作用,葡激酶的高级结构,抗原性等问题以及近年来有关葡激酶作为新一代溶栓的研究进展进行了综述,并指出进一步利用蛋白质工程,对葡激酶进行分子改造的设想。     

单链尿激酶型纤溶酶原激活物的结构和性质

单链尿激酸型纤溶酶原激活物(scuPA)是一种丝氨酸蛋白酶,由411个氨基酸组成单一多肽链结构,是尿激酶的前体形式。它可特异地激活血栓局部的纤溶酶而启动纤溶系统,并与组织型纤溶酶原激活物(tPA)有协同作用,是一种有广泛前途的溶栓物质。     

单链尿激酶型纤溶酶原激活剂Kringle结构域催化功能探讨

 Kringle(K)结构域广泛存在于与凝血和纤溶相关的各种因子中 .虽然 K结构域在一级结构上是一种比较保守的结构域 (与其他结构域相比 ) ,但是 K结构域的功能在各种因子中的作用有很大的区别 .为探讨单链尿激酶型纤溶酶原激活剂 (scu- PA)的 K结构域功能 ,构建了在 scu- PA的 K结构域的 1 1 8位 Gly与 1 1 9位 Leu之间插入 PRGDWR序列的突变体 (称为 insert mutant B,In B) ,并测定了野生型 scu- PA与 In B的纤溶相关反应的动力学常数 . scu- PA与 In B水解 S- 2 4 4 4反应的 Km 值无明显变化 (分别为 60 .4与 56.8μmol·L-1) ,而 In B的 kcat值 (0 .33s-1)比 scu- PA的 kcat值 (7.31 s-1)降低很多 ;In B激活纤溶酶原反应的 Km 值 (0 .397μmol· L-1)比 scu- PA Km 值(0 .648μmol·L-1)降低 40 % ,但 kcat值 (0 .0 1 65s-1)比 scu- PA的 kcat值 (0 .0 62 6s-1)降低 74% .以上结果说明 :K结构域主要与反应活性相关 ,而与酶及底物的亲和性无关 .     

凝血酶激活的单链尿激酶型纤溶酶原激活剂的构建、表达、纯化和性质研究

用Ｋｕｎｋｅｌ突变法,将单链尿激酶型纤溶酶原激活剂（ｓｃｕ－ＰＡ）ｃＤＮＡ基因中编码Ｐｒｏ１５５—Ｌｙｓ１５８的片段定点突变,并将此突变的ｓｃｕ－ＰＡ（ｔｓｃｕ－ＰＡ）的ｃＤＮＡ克隆到表达载体ｐＣＭ－β－ｎｅｏ中,与ｐＣＭ－ｄｈｆｒ共转染ＣＨＯ／ＤＨＦＲ－细胞．获得的稳定表达株在无血清培养基中２４ｈ的表达量为６２０ＩＵ／１０６细胞．经锌离子螯合Ｓｅｐｈａｒｏｓｅ亲和层析得到ｔｓｃｕ－ＰＡ纯品．ＳＤＳ－ＰＡＧＥ显示ｔｓｃｕ－ＰＡ分子量为５３ｋＤ左右,与预期的结果相符．ｔｓｃｕ－ＰＡ是由凝血酶激活而不是由纤溶酶激活,但激活后也能转变为双链分子（ｔｃｕ－ＰＡ）．ｔｓｃｕ－ＰＡ仍保持了ｓｃｕ－ＰＡ的血纤维蛋白亲和性．酶动力学研究表明,激活后的ｔｓｃｕ－ＰＡ水解Ｓ２４４４的Ｋｍ和Ｋｃａｔ值与高分子量尿激酶（ＨＵＫ）相似．体外溶栓实验结果表明,ｔｓｃｕ－ＰＡ可以选择性地溶解富含凝血酶的血凝块,对贫凝血酶的血凝块作用不大     

重组抗人活化血小板单链抗体-尿激酶原导向溶栓剂的基因构建及表达

为了获得特异性高的导向溶栓药物,应用PCR技术,得到抗人活化血小板单抗(SZ-51)的Fab′基因片段。再用酶切方法,将Fab′中CH1基因片段替换成合成的连接分子(linker)基因,构建成单链抗体基因,并插入到人尿激酶原分泌肽基因及低分子量单链尿激酶(scu-PA-32k)之间,最终构建成重组抗人活化血小板单链抗体-尿激酶原融合蛋白基因。此融合蛋白基因在昆虫细胞中得到表达。纯化的表达产物SDS-PAGE鉴定,其分子量约为60kD,与预期值相符。其比活为9000IU/mg蛋白。ELISA法初步证明此重组的融合蛋白具有与活化血小板抗原结合特异性。     

人胎肺细胞的条件化培养液中两种类型纤溶酶原活化物的分离

用正常人胎肺细胞体外培养,从其培养液中分离纤溶酶原活化物（ＰＡ）,通过ＣＭ－ＳｅｐｈａｄｅｘＣ－５０层析,硫酸铵沉淀和Ｆｉｂｒｉｎ－Ｓｅｐｈａｒｏｓｅ,Ｌｙｓｉｎｅ－Ｓｅｐｈａｒｏｓｅ亲和层析及ＳｅｐｈａｄｅｘＧ－５０凝胶过滤等步骤,从１０．５ｌ条件培养液中分离纯化得到两种类型的纤溶酶原活化物,ｔ－ＰＡ９０μｇ,ｕ－ＰＡ８００μｇ．在还原条件下ＳＤＳ－ＰＡＧＥ均显示单带,分子量ｔ－ＰＡ为７２ｋＤ,ｕ－ＰＡ为５４ｋＤ,纤溶比活分别为１５６０００ＩＵ／ｍｇ蛋白和１０６０００ＩＵ／ｍｇ蛋白．     

CHO细胞表达的抗炭疽保护性抗原人源化抗体的纯化及质量控制分析

目的:建立CHO细胞表达的抗炭疽保护性抗原人源化单抗纯化工艺和质量控制方法。方法:收获50 L生物反应器中无血清悬浮培养的CHO工程细胞培养液,通过高速离心去除细胞及碎片后超滤浓缩上清液,经亲和层析、SPFF阳离子交换层析后,将所得目的蛋白质经G25凝胶柱更换缓冲液以完成纯化;对纯化的产品进行单抗鉴别(Western印迹)、相对分子质量(SDS-PAGE和MOLDI-TOF)、纯度(SEC-HPLC)、生物学活性(毒素中和试验)、产品相关杂质(SEC-HPLC检测聚集体、降解产物)、工艺相关杂质(ELISA分析残余宿主蛋白、残余蛋白A)、安全性(凝胶法检测内毒素、薄膜过滤法考察无菌)分析。结果:样品回收率达61.7%;单抗鉴别实验阳性;MOLDI-TOF测定完整分子的相对分子质量为147 995,与预期相符;单体比例为99.25%,二聚体比例为0.75%;EC50值为0.1516μg/m L。残余宿主蛋白、残余蛋白A、内毒素、无菌检查结果符合药典要求。结论:初步建立了纯化工艺和质量控制方法,为抗炭疽人源化单抗药物的研制奠定了基础。     

Utilization of side-chain precursors for penicillin biosynthesis in a high-producing strain of Penicillium chrysogenum

Utilization of the side-chain precursors phenoxyacetic acid (POA) and phenylacetic acid (PA) for penicillin biosynthesis by Penicillium chrysogenum was studied in shake flasks. Precursor uptake and penicillin production were followed by HPLC analysis of precursors and products in the medium and in the cells. P. chrysogenum used both POA and PA as precursors, producing phenoxymethylpenicillin (penicillin V) and benzylpenicillin (penicillin G), respectively. If both precursors were present simultaneously, the formation of penicillin V was blocked and only penicillin G was produced. When PA was added at different times to cells that were induced initially for POA utilization and were producing penicillin V, the POA utilization and penicillin V formation were blocked, whereas the cells started utilizing PA and produced penicillin G. The blocking of the POA turnover lasted for as long as PA was present in the medium. If POA was added to cultures induced initially for PA utilization and producing penicillin G, this continued irrespective of the presence of POA. Utilization of POA increased concomitant with depletion of PA from the medium. Analysis of cellular pools from a growing cell system with POA as precursor to which PA was added after 48 h showed that the cellular concentration of POA was kept high without production of penicillin V and at a concentration comparable to the concentration in the medium. The cellular concentration of POA was higher than the concentration of PA that was utilized for penicillin G production. Correspondence to: S. Havn Eriksen     

血纤蛋白粘附肽与低分子量单链尿激酶融合产物活性分析

人工合成了血纤蛋白粘附肽基因,构建了粘附肽与低分子量单链尿激酶ｃＤＮＡ的融合基因,在大肠杆菌中表达了融合基因。融合基因表达产物的抗原性和天然尿激酶相同,并具有尿激酶的溶纤活性和粘附肽的抗纤维蛋白单体聚合的功能。     

Improvement of posttranslational bottlenecks in the production of penicillin amidase in recombinant Escherichia coli strains

Using periplasmic penicillin amidase (PA) from Escherichia coli ATCC 11105 as a model recombinant protein, we reviewed the posttranslational bottlenecks in its overexpression and undertook attempts to enhance its production in different recombinant E. coli expression hosts. Intracellular proteolytic degradation of the newly synthesized PA precursor and translocation through the plasma membrane were determined to be the main posttranslational processes limiting enzyme production. Rate constants for both intracellular proteolytic breakdown (k(d)) and transport (k(t)) were used as quantitative tools for selection of the appropriate host system and cultivation medium. The production of mature active PA was increased up to 10-fold when the protease-deficient strain E. coli BL21(DE3) was cultivated in medium without a proteinaceous substrate, as confirmed by a decrease in the sum of the constants k(d) and k(t). The original signal sequence of pre-pro-PA was exchanged with the OmpT signal peptide sequence in order to increase translocation efficiency; the effects of this change varied in the different E. coli host strains. Furthermore, we established that simultaneous coexpression of the OmpT pac gene with some proteins of the Sec export machinery of the cell resulted in up to threefold-enhanced PA production. In parallel, we made efforts to increase PA flux via coexpression with the kil gene (killing protein). The primary effects of the kil gene were the release of PA into the extracellular medium and an approximately threefold increase in the total amount of PA produced per liter of bacterial culture.     

Selection of the medium for the simultaneous synthesis of an antibiotic, protease and pigment by a Nocardia fructiferi culture

Using method of mathematical planning of experiment the culture medium ensuring the simultaneous intensive production of ristomycin, protease and violet pigment by Nocardia fructiferi has been worked out.     

Study the influence of culture conditions on rennin production by Rhizomucor miehei using solid-state fermentations

Investigations were conducted on the production of Rennin enzyme from the fungi Rhizomucor miehei 3420 NRRL using Solid-State fermentation. Wheat bran was used as a substrate. The influence of moisture content, incubation temperature, and the initial pH of fermentation medium were studied. The protein content, milk clotting activity (MCA), specific activity, proteolytic activity (PA), and (MCA/PA) ratio of the extracted enzyme were calculated after 4 days of incubation to evaluate the quality of the enzyme. The results showed that the optimal conditions for production were as follows: incubation temperature of 40 °C, moisture content of 60%, and pH of (3). Under these conditions, a production process of Rennin enzyme was established, and the values of protein content, milk clotting activity, specific activity, proteolytic activity, and (MCA/PA) ratio reached to 4 mg/mL, 600 SU/mL, 150 SU/mg, 45 PU/mL, 13.3 respectively.